Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 1

Interventions

Dexamethasone 70Lenalidomide 39daratumumab 37Bortezomib 33pomalidomide 31Specimen Handling 28Biopsy 26carfilzomib 24Cyclophosphamide 24Calcium Dobesilate 24Magnetic Resonance Spectroscopy 21dexamethasone acetate 16dexamethasone 21-phosphate 16auricularum 16isatuximab 14fludarabine 13belantamab mafodotin 12iberdomide 11Melphalan 11talquetamab 10selinexor 9X-Rays 8tocilizumab 7fludarabine phosphate 7elotuzumab 6Nuclear Medicine Department, Hospital 5trametinib 4pembrolizumab 4nirogacestat 4Thalidomide 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Loratadine × Plasma cell × 30 days × Clear all
NCT04211259 2026-05-29

Loratadine for the Reduction of G-CSF Induced Bone Pain in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization

Rutgers, The State University of New Jersey

Phase EARLY_PHASE1 Recruiting
70 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡